持续周围神经阻滞治疗截肢后幻肢痛的患者中心结果:多中心随机试验次要结局
该多中心随机双盲试验纳入截肢后幻肢痛患者,比较6天持续周围神经阻滞使用罗哌卡因(n=71)与生理盐水(n=73)的效果。再分析显示,罗哌卡因组57%的患者在平均和最差幻肢痛上达到至少2分改善(安慰剂组分别为26%和25%,p<0.001),53% vs 30%报告疼痛改善(95%CI 1.7 (1.1,2.7),p=0.008)。患者定义的小、中、大疼痛改善中位值分别为2、3、5分(数字评定量表)。
要点
- 6天罗哌卡因持续周围神经阻滞使幻肢痛临床相关改善几率提高一倍以上。
- 患者定义的小、中、大疼痛改善中位值分别为2、3、5分(0-11数字评定量表)。
- 简明疼痛量表干扰亚量表(0-70)对应小、中、大改善的中位值分别为8、22、39。
核心结论
- 对于截肢后幻肢痛患者,6天持续周围神经阻滞使疼痛强度达到临床相关改善的几率提高一倍以上。
研究设计与样本
- 多中心随机双盲试验的次要结局分析,纳入截肢后幻肢痛患者,随机接受6天持续周围神经阻滞罗哌卡因(n=71)或生理盐水(n=73)。
主要发现
- 罗哌卡因组57%的患者在基線后4周平均和最差幻肢痛数字评定量表上达到至少2分改善,安慰剂组分别为26%(p<0.001)和25%(p<0.001)。
- 基線后4周,罗哌卡因组53%的患者评价疼痛改善,安慰剂组为30%(95%CI 1.7 (1.1,2.7),p=0.008)。
- 全部患者合并,4周时幻肢痛数字评定量表改善中位值(IQR)小、中、大分别为2(0-2)、3(2-5)、5(3-7)。
- 简明疼痛量表干扰亚量表(0-70)改善中位值(IQR)小、中、大分别为8(1-18)、22(14-31)、39(26-47)。
临床怎么用
- 对于截肢后幻肢痛患者,可考虑使用6天持续周围神经阻滞罗哌卡因以增加临床相关疼痛改善的机会。
- 评估镇痛改善时,可参考患者定义的疼痛评分改善阈值(小=2分,中=3分,大=5分)和简明疼痛量表干扰改善阈值(小=8,中=22,大=39)。
局限性
- 本文为原试验的次要结局再分析,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We previously reported that a 6-day continuous peripheral nerve block reduces established postamputation phantom pain. To provide patients and providers with the information to best inform treatment decisions, here we reanalyze the data and present the results in a more patient-centered format. We also provide information on patient-defined clinically relevant benefits to facilitate evaluation of available studies and guide future trial design. METHODS: The original trial enrolled participants with a limb amputation and phantom pain who were randomized to receive a 6-day continuous peripheral nerve block(s) of either ropivacaine (n=71) or saline (n=73) in a double-masked fashion. Here we calculate the percentage of each treatment group that experienced a clinically relevant improvement as defined by previous studies as well as present what the participants of our study defined as small, medium, and large analgesic improvements using the 7-point ordinal Patient Global Impression of Change scale. RESULTS: Among patients who were given a 6-day ropivacaine infusion, 57% experienced at least a 2-point improvement on the 11-point numeric rating scale in their average and worst phantom pain 4 weeks postbaseline as compared with 26% (p<0.001) for average and 25% (p<0.001) for worst pain in patients given a placebo infusion. At 4 weeks, the percentage of participants rating their pain as improved was 53% for the active vs 30% for the placebo groups (95% CI 1.7 (1.1, 2.7), p=0.008). For all patients combined, the median (IQR) phantom pain Numeric Rating Scale improvements at 4 weeks considered small, medium, and large were 2 (0-2), 3 (2-5), and 5 (3-7), respectively. The median improvements in the Brief Pain Inventory interference subscale (0-70) associated with small, medium, and large analgesic changes were 8 (1-18), 22 (14-31), and 39 (26-47). CONCLUSIONS: Among patients with postamputation phantom pain, a continuous peripheral nerve block more than doubles the chance of a clinically relevant improvement in pain intensity. Amputees with phantom and/or residual limb pain rate analgesic improvements as clinically relevant similarly to other chronic pain etiologies, although their smallest relevant improvement in the Brief Pain Inventory was significantly larger than previously published values. TRIAL REGISTRATION NUMBER: NCT01824082.
引用
- Ilfeld BM, Khatibi B, Maheshwari K, et al. Patient-centered results from a multicenter study of continuous peripheral nerve blocks and postamputation phantom and residual limb pain: secondary outcomes from a randomized, clinical trial. Reg Anesth Pain Med. 2023. PMID: 36894197. doi:10.1136/rapm-2023-104389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。